SHENZHEN, China, Oct. 16, 2025 /PRNewswire/ — JMGO unveils its latest innovation, the O2S Ultra, an intelligent ultra-short throw projector that redefines the home cinema experience.

Capable of projecting a 100-inch image from just 16.8cm away from the wall, the O2S Ultra offers the shortest throw ratio on the market. It instantly transforms any living room into a true movie theater, combining exceptional image power, immersive Dynaudio sound, and refined design.

Engineered to adapt to any space, the O2S Ultra projects a 100-inch image from just 16.8cm away from the wall. Easy to install and discreet, it simply needs to be placed on an piece of furniture to deliver a cinematic experience without losing space or requiring complex setup.

Its MALC™ 3.0 Tri-Laser system delivers a brilliant 4K image covering 110% of the BT.2020 color gamut, with 3,600 ISO lumens of brightness and a 3,000,000:1 dynamic contrast ratio. Every detail is sharp, every color accurate, ensuring total immersion, even in bright light.

The experience extends beyond visuals. Developed in collaboration with Dynaudio, the O2S Ultra’s sound system delivers powerful and balanced audio, certified Dolby Audio and DTS-HD, for a complete cinema experience.

With Google TV and Netflix built in, users have access to over 10,000 entertainment apps, making every viewing session seamless, connected, and intuitive.

Compact and elegant, the O2S Ultra combines design and technology. Its recycled-material casing, discreet lines, and perfect integration into the living room, combined with the optional 120″ motorized screen, create a stylish and immersive home cinema setup.

Available now at a recommended retail price of 2,999.99USD. A special launch offer is available until October 31, 2025, with a 200USD discount at JMGO official store and Best Buy.

With the launch of the O2S Ultra, JMGO reaffirms its commitment to pushing the boundaries of home entertainment. By combining cutting-edge technology, sustainable design, and intuitive user experience, the brand is paving the way for a new generation of intelligent projectors designed to transform every living room into a true cinema space.

At ASHG, an early access customer from the London Health Sciences Center Research Institute demonstrated the power of the 5-base genome for accelerating resolution of rare disease cases 

Proprietary 5-base chemistry and novel DRAGEN algorithms enable dual-omic inquiry, providing researchers with new tool for precision medicine breakthroughs 

SAN DIEGO, Oct. 16, 2025 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) announced the release of its novel 5-base solution, enabling researchers to pursue broader biological questions with accuracy and ease. The 5-base solution marks a major advancement in scalable multiomic analysis, enabling simultaneous detection of both genomic variants and DNA methylation from a single sample, in a streamlined, cost-effective workflow. Powered by Illumina’s proprietary 5-base chemistry and custom DRAGEN algorithms, the solution delivers high-resolution insights into both the methylome and genome while reducing complexity and cost. This powerful workflow can help researchers uncover disease mechanisms, detect and discover biomarkers for cancer and genetic disease, study disease progression, identify drug targets, and advance precision medicine.

“Our new 5-base solution reflects the many ways we are redefining what’s possible through the power of multiomics,” said Steve Barnard, chief technology officer of Illumina. “It’s already driving insights in areas ranging from oncology to rare disease and elucidating the role of epigenetic regulation in human health—all in a cost-effective, scalable workflow.”

Key features of the 5-base solution

Unlike conventional methylation conversion technologies, Illumina’s proprietary conversion chemistry selectively converts methylated cytosine to thymine. This selective conversion of methylated cytosines preserves genomic complexity and variant information in the sequencing library, generating maximum biological insights in each run.

Customers can choose from two kits, Illumina 5-Base DNA Prep and Illumina 5-Base DNA Prep with Enrichment, both commercially available following a successful early-access program. Illumina 5-Base DNA Prep offers whole-genome coverage and Illumina 5-Base DNA Prep with Enrichment allows the user to focus on select genomic regions of interest through targeted enrichment. Both kits can detect DNA methylation at a single-base resolution.

The library preparation and sequencing of these kits are compatible with Illumina NovaSeq Systems and the NextSeq 2000 System. Novel DRAGEN algorithms allow for simultaneous methylation profiling and high-accuracy genomic variant calling. Illumina Connected Multiomics combines multiomic data with powerful statistical visualization and interpretation, making deep biological insights possible. This end-to-end Illumina pipeline unlocks the future of discovery and drug development.

Unlocking streamlined discovery in rare disease

London Health Sciences Centre Research Institute’s research chair in Clinical Genomics and Epigenomics, Bekim Sadikovic, is one of over 50 early testers applying the 5-base solution to their multiomic research questions.

“Illumina’s comprehensive 5-base technique—with the ability to use the combined genome sequencing and epigenetic data simultaneously—has the potential to change the way we look at functional genomics,” said Sadikovic. “This is going to allow us to add layers of insight that go beyond genetics alone, toward a more complete view of rare diseases.”

Sadikovic presented at the American Society of Human Genetics (ASHG) annual meeting in Boston, where he illustrated the Illumina 5-base solution’s ability to detect variants and methylation signatures across rare disease samples. His talk “Validation of integrated platform for simultaneous detection of genetic variants and DNA methylation episignatures in rare diseases” was held in Room 153ABC on October 15 from 12:00 to 1:00 PM ET.

In addition to its new 5-base solution, Illumina is showcasing the new Illumina Protein Prep product along with its full range of multiomics technology this week at ASHG. Those interested in the ASHG talks but unable to attend the presentation can preregister for the on-demand webinar here. You can see all of Illumina’s multiomics solutions in development and commercially available here.

Use of forward-looking statements

This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

SHANGHAI, Oct. 16, 2025 /PRNewswire/ — A report from Ringiertrade.

MedTec China 2025, which took place at the Shanghai World Expo Exhibition & Convention Center (SWEECC) from September 24-26, served as the ideal platform to promote the latest innovations in the production of medical devices. At this exhibition, ROSTI Integrated Manufacturing Solutions (Suzhou) Co., Ltd. (ROSTI) provided visitors with interesting glimpse of its medical device design, assembly and production solutions aimed at the highly dynamic Asian markets. 

ROSTI, a pioneer injection molding and assembly for the medical device industry, highlighted its technical expertise in the field of medical devices – from conceptualization and design to production and final output. In China, ROSTI offers optical injection molding and assembly services. Aside from its high-quality injection molding and assembly services, it also manages subsequent packaging, sterilization, overseas market documentation preparation, as well as regulatory consulting. Pat Williams, Senior Vice President of ROSTI Asia, together with Yifei Dai, Managing Director of Industrial Design Consultancy (IDC), discussed how their partnership led to the innovative designs of the medical devices that were presented at the ROSTI booth.

Combined expertise in the medical devices field 

At MedTech China 2025, ROSTI put into centerstage several new products that reflect its strong capabilities in the field of medical devices. One of these products is an innovative dermatology device designed for a US customer. “This product was the first project that we had with a design partner and was launched into production. It exemplifies the importance of a strong partnership between ROSTI and a design company that has enabled the development of a good design where we achieved precision and efficient manufacturing by working together with a design partner. The result is an excellent product that was launched and delivered to the customer, and will be commercially available,” according to Pat Williams. 

ROSTI, in partnership with IDC, also showed off a skincare device that was launched in early last year. Another product is a smart device that connects to IOT on the mobile phone, which, according to Williams, “is a differentiated change from the first smart device that we’ve launched in the market as a result of our cooperation with our design partner.” ROSTI has also recently gone into surgical stapler with very high precision – which was produced first in the US and later in Suzhou. A number of products that were previously produced in the Europea facility of ROSTI have now gone into production at the ROSTI facility in China.  

Another strong point for ROSTI is how its customers benefit from the company’s materials that are contained in the FDA-backed masterfile. This allows customers to use ROSTI’s 3D printing technology to make the initial device using FDA-backed materials, obtain FDA approval and conduct clinical test before going into mass production. “We provide that bridge from prototype to a functional prototype stage to help our customers lower their costs and save time through this process,” according to Williams. Materials that conform to stringent medical standards and have been approved for use in different sterilization methods are required for reusable medical device, as well as for single use medical device. With ROSTI’s expertise, their customers are able to easily comply to the standards required for various types of medical devices. 

As ROSTI’s partner in the designing the innovative products that it’s able to offer its customers, IDC has been engaged in mechanical engineering and electrical engineering starting from the initial conceptualization, design and manufacture. At the exhibition booth, IDC presented some of its designs, among them, a continuous positive airway pressure device that is intended for people who suffer from a condition known as sleep apnea. The device was also found useful during the Covid pandemic where it was able to save lives.  According to Yifei Dai, Managing Director of IDC, “Our customers approach us with design challenges as well as reliability and usability issues, which we help resolve. Then we focus on the key innovations that can be introduced on the product.” IDC performs usability studies, work with the medical professionals and conduct user trials. As Yifei Dai put it: “IDC has invented a new way of operating the medical devices we design to make them more comfortable and enable ease of use that also support the medical practitioners.”  IDC has also designed medical devices that enable the user to feel proud and excited about wearing the device because of several factors such as the device being more lightweight and usable. This has been made possible through sophisticated manufacturing process that has been part of the design stage. 

The main difference between IDC with other design companies is that IDC is a full service design agency that can basically start from product design research all the way through to production support. As Yifei Dai explains, “IDC works with the customer in making sure that the product can be launched to the market properly, so this involves conducting clinical research and industrial ID design, mechanical software design and design to support manufacturing transfers – an entirely complete package. IDC brings value to the Chinese medical device company through product innovation where we create a product to solve the clinical problems.” IDC helps solve the problems through innovations that will enable the creation of new patent opportunities for its customer so they can register new patent. 

ROSTI and IDC working together have achieved the target results, with ROSTI serving as advisor to IDC during the design process – a very important aspect in getting the manufacturing work team working together to understand the feasibility of every design project. 

Advancing in China and the rest of the world  – future plans and strategies

ROSTI is celebrating its 25^th anniversary in China. Over the years, ROSTI has been moving forward in the China market with its innovations leaning toward providing high quality products and services that respond to the everchanging demands of customers  in China and the rest of the Asian region. “Being in such a huge market as China requires us to keep on adding value to what we offer. We have to keep reinventing and now, ROSTI is providing  end-to-end solutions to our customers, working with our manufacturing partners, and our design partners. We have gone forward in the medical sector by being a contract development manufacturing organization where we can offer what our customers need, and that’s what we’ve developed in the last 25 years,” according to Williams. To support the upsurge in its medical business, ROSTI has sought the approval of a plan for an expanded 500-square-meter 100,000-level cleanroom which aims to meet the demands of both new and existing customers, and also highlights ROSTI’s decision to further strengthen its hold in the medical field. The expansion project is scheduled for completion in February 2026.  The company has also been certified under ISO 13485 medical standards.

ROSTI currently has two hubs for its medical business – one in China and another in Poland. These hubs are being expanded. In Asia, the facilities in Malaysia and Singapore are supporting the medical device business with the expansion of the cleanroom in Malaysia also being planned. With the actual drive toward regulatory compliance getting more stringent in China and in some cases being higher than other markets, ROSTI and IDC working together offer customers value added services through improved product design and efficient manufacturing process that meet global standards.

About ROSTI Group

Founded in 1944 with headquarters in Malmö, Sweden, ROSTI Group is a global technology-led plastic injection molding company and contract manufacturer to some of the world’s leading manufacturers in the packaging, consumer appliances, business machines and medical sectors.The Group has 3,200 existing employees across 8 production facilities in Europe and Asia. For more information, visit: www.rosti.com